The impact of frailty on prescribing patterns and medication tolerability in interstitial lung disease

Pharmacological treatment for interstitial lung disease (ILD) is often poorly tolerated, with at least 20% of patients experiencing adverse effects requiring treatment discontinuation [1–4]. Nearly half of patients with fibrotic ILD are frail or vulnerable and have worse survival compared to fit patients [5]. In this study, we aimed to determine whether prescribing practices for ILD treatments and medication tolerability differ based on a patient's frailty, potentially explaining worse outcomes among frail individuals [5]. Frail patients with ILD are less likely to receive and tolerate antifibrotics but have similar likelihood of receiving and continuing immunosuppression compared to fit patients https://bit.ly/4nME9dJ